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Abstract
Introduction: 131-I treatment of nodular, especially nontoxic, goitre is still reserved mainly for elderly patients, whose numerous con-
comitant diseases disqualify them from surgery. Therapy often involves isolation and is available only in selected centres, which may be 
located far from some patients’ places of residence, which is inconvenient for elderly people. 
The aim of the study was to assess the effectiveness of outpatient fractionated 131-I treatment of patients with large nodular goitres, as 
well as to evaluate complications and the factors affecting treatment results.
Material and methods: The study included 35 patients with a large nodular goitre. Thyroid volume and treatment results were evaluated 
using US and CT neck examination. 
Results: Mean thyroid volume prior to treatment was 104.36 mL (range 36.23–301.09 mL). An average administered 131-I activity was 
1806 MBq (range 800–4000). The average reduction of goitre volume was 43.18% (range –17.23–89.66%). Final treatment results correlated 
with the thyroid size reduction obtained three months after treatment (r = 0.74; p = 0.001). Symptoms of transient hyperthyroidism were 
observed in 8.57% of patients, in 5.4% Graves disease was induced (including severe Graves’ orbitopathy in 2.7%), and in 2.86% TRAb 
increase without development of hyperthyroidism was observed. The treatment results were not influenced by initial thyroid volume 
(r = –0.01; p = 0.95). An increase in thyroid volume during the treatment was reported in 20% of patients, with a mean increase of 22.3% (range 
0.63–55.03%). Post-treatment hypothyroidism was diagnosed in 42.9% of patients. One patient was diagnosed with salivary gland damage. 
Conclusions: Fractionated 131-I treatment of large nodular goitres is an effective method, the results of which are comparable to those 
obtained from the administration of one-time high doses of radioiodine. (Endokrynol Pol 2015; 66 (4): 301–307)
Key words: radioiodine; radioiodine treatment; goitre; nontoxic goitre 
Streszczenie
Wstęp: Leczenie 131-I wola guzowatego olbrzymiego, szczególnie obojętnego, nadal zarezerwowane jest głównie dla pacjentów w star-
szym wieku, z licznymi chorobami towarzyszącymi dyskwalifikującymi ich z leczenia zabiegowego. Terapia, szczególnie w przypadku 
dużych rozmiarów wola wiąże się z izolacją po podaniu 131-I, a leczenie jest możliwe tylko w wybranych ośrodkach często oddalonych 
od miejsca zamieszkania, co jest utrudnieniem dla osób starszych.
Celem pracy była ocena skuteczności leczenia wola olbrzymiego 131-I w warunkach ambulatoryjnych dawkami frakcjonowanymi 
z analizą czynników wpływających na efekt terapii oraz oceną jej powikłań.
Materiały i metody: Analizą objęto 35 osób z wolem guzowatym olbrzymim. Ocenę objętości tarczycy i efektów leczenia wykonano 
z użyciem badań USG oraz CT szyi. 
Wyniki: Średnia objętość wola przed leczeniem wynosiła 104,36 mL (zakres 36,23–301,09), a średnia podana aktywność 131-I to 
1806 MBq (zakres 800–4000). Uzyskano redukcję objętości wola średnio o 43,18% (zakres –17,23–89,66%). Ostateczny efekt leczenia 
korelował z poziomem redukcji uzyskanym po 3 miesiącach leczenia (r = 0,74; p = 0,0010). Efekt leczenia nie zależał od wyjściowej wiel-
kości wola (r = –0,01; p = 0,95). Objawy przejściowej nadczynności tarczycy obserwowano u 8,57% leczonych, u 5,4% wyindukowano 
chorobę Gravesa-Basedowa (u 2,7% ciężką orbitopatię) u 2,86% zaobserwowano wzrost miana przeciwciał przeciw receptorowi TSH 
bez objawów nadczynności tarczycy. Przejściowo powiększenie tarczycy w trakcie leczenia obserwowano u 20% leczonych, a objętość 
gruczołu wzrosła średnio o 22,3% (zakres 0,63–55,03). Niedoczynność tarczycy po zakończeniu leczenia stwierdzono u 42,9% pacjentów. 
W jednym przypadku obserwowano, nieopisywane wcześniej po stosowaniu małych dawek 131-I, popromienne uszkodzenie ślinianek.
Wnioski: Leczenie wola guzowatego olbrzymiego frakcjonowanymi dawkami 131-I jest leczeniem skutecznym, o efektach porównywal-
nych do stosowania dużych jednorazowych dawek radiojodu. (Endokrynol Pol 2015; 66 (4): 301–307)
Słowa kluczowe: radiojod; jod radioaktywny; leczenie radiojodem; wole obojętne; wole olbrzymie
This work was supported by the National Science Centre (NCN) from funds for science in 2009-2013 as research project number N N402 
477137.
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The final group consisted of 35 patients (33 women, 
2 men) with large nodular goitre, who were adminis-
tered 131-I. The characteristics of the patient group is 
shown in Table I.
131-I treatment
Radioiodine was administered orally, with an activ-
ity of 800 MBq per capsule. The radioiodine activity 
was determined using modified Marinelli’s formula [7]: 
A = (C × V × 100)/U
A — administered 131-I activity [MBq]; C — constant, 
usually between 3 and 5 [MBq/g of thyroid tissue], in the 
study the assumed value was 4.44 MBq/g; V — thyroid 
mass [g] (based on US study); U — thyroid 131-I uptake 
(RAIU) 24 hours after 131-I administration (%).
The calculated 131-I activity was fractionated, with 
a single administered activity of 800 MBq. In the case 
of calculated activities < 800 MBq a full dose (800 MBq) 
was administered. In the case of calculated activities 
> 800 MBq, 800 MBq was administered in repeated doses. 
In order to avoid the “thyroid stunning” effect, consecutive 
radioiodine doses were administered every three months.
Imaging evaluation 
US examinations were performed in all patients prior 
to treatment, as well as 3, 6, and 12 months afterwards. 
All measurements were taken by the same radiologist 
using a SIEMENS S2000 (Siemens, Erlangen, Germany) 
with a 18L6 HD linear transducer (5.5–18 MHz) and 
6C2 convex transducer 6C2 (2–6 MHz).
The US estimation of thyroid volume was based on 
the ellipsoid formula, adding the volumes of both lobes 
measured using the following formula [8]:
Introduction
Over the last two decades radioiodine treatment of 
toxic and nontoxic nodular goitres has gained consid-
erable popularity. However, surgery still remains the 
preferred method. In toxic goitre one of the options 
is antithyroid drug treatment. Nevertheless, it cannot 
be used permanently due to its negative impact on 
the thyroid volume, causing further goitre growth [1, 
2]. 131-I treatment, especially in nontoxic goitre, has 
thus far been reserved mainly for elderly patients, 
whose numerous concomitant diseases disqualify 
them from surgery [3, 4]. Without hyperthyroidism-
related symptoms, patients with long-standing 
nontoxic nodular goitres and those on antithyroid 
drug therapy are not willing to undergo any other 
treatment, even relatively non-invasive 131-I admin-
istration, especially when it involves post-treatment 
isolation. The administration of rhTSH shortens the 
hospitalisation period, yet in many countries no 
reimbursement is given for rhTSH nodular goitre 
treatment [5, 6]. Moreover, this method is available 
only in selected centres that offer hospitalisation. The 
centres are often located a considerable distance from 
elderly patients’ place of residence, which causes 
great inconvenience to them. 
The aim of the study was to assess the effectiveness 
of outpatient fractionated 131-I treatment of patients 
with large nodular goitres, with evaluation of the treat-
ment complications and the factors affecting treatment 
results.
Material and methods
The study included 37 patients with nodular goitres 
(25 euthyroid, 10 with subclinical hyperthyroidism), 
who did not give their consent to surgical treat-
ment, were disqualified from surgery due to their 
concomitant diseases, or were diagnosed with post-
surgical goitre regrowth. The study was conducted 
in the Department of Endocrinology and Internal 
Medicine and the Outpatient Endocrinology Clinic 
of the Medical University of Gdansk (MUG) between 
2009 and 2012. The treatment was conducted in 
the Department of Nuclear Medicine of the same 
University. The scheme of the study and treatment 
was approved by the MUG Independent Bioethics 
Commission. During the study, two patients were 
excluded from evaluation after they were diagnosed 
with radioiodine-induced Graves disease, and in one 
of them symptoms of severe Graves orbitopathy were 
observed. Prior to the treatment, the patient did not 
show any symptoms of Graves hyperthyroidism, she 
had negative TRAb, and she was a smoker. 
Table I. Basic characteristics of the study group
Tabela I. Charakterystyka podstawowa badanej grupy
Study group N=35
Age (years) median (range) 65.63 (49.00–84.00)
Duration of symptoms 
(years)
median (range) 15.83 (1.00–50.00)
L-T4 dosage [µg/day] median (range) 9.23 (0–75.0)
Previous L-T4 therapy N (%) 6 (17.1%)
Previous strumectomy N (%) 6 (17.1%)
Family history N (%) 13 (37.1%)
Smokers N (%) 17 (48.6%)
Pressure on or dislocation 
of trachea
N (%) 21 (60.0%)
Substernal goitre N (%) 17 (48.6%)
Euthyroid N (%) 25 (71.4%)
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V = H · W · D · p 6
where:
H — height [cm], W — width [cm], D — depth [cm]
All patients with suspicion of malignancy in US 
additionally underwent FNAB (fine needle aspiration 
biopsy). 
CT thyroid assessment without contrast enhance-
ment was conducted both before and 12 months after 
the treatment. All examinations were performed with 
the same GE LightSpeed 32-Slice CT Scanner (GE 
Healthcare Technologies, Wisconsin, USA) by using the 
spiral technique. Images were taken in sequences every 
5 mm. Thyroid volume was calculated planimetrically 
using Siemens SYNGO.VIA software.
Evaluation of hormonal function of the gland
Serum concentration of TSH (reference values: 
0.35–4.94 μIU/mL), fT4 (reference values: 9.01–19.05 
pmol/L), and fT3 (reference values: 2.63–5.7 pmol/L) 
as well as anti-TPO and anti-TG antibodies (negative 
< 150 IU/mL and < 4.11 IU/mL, respectively) were 
measured by immunoassay using an ARCHITECT 
analyser (Abbott Laboratories, USA). Thyrotropin 
receptor antibodies (TRAb) antibodies (negative < 
1.8 IU/L) were measured by ELISA assay using a EU-
ROIMMUN analyser. 
Statistical analysis
Statistical calculations were performed using the Stat-
Soft, Inc. (2011) STATISTICA data analysis software 
system, version 10.0. (www.statsoft.com) and MS Excel 
spread sheets. The significance of differences between 
the two groups was evaluated using tests of statistical 
significance: Student’s t-test or the Mann-Whitney U 
test. The significance of differences between more than 
two groups was tested using the F-test (ANOVA) or 
Kruskall-Wallis one-way analysis of variance. In the 
case of statistically significant differences between 
the groups, post hoc tests were used (the Tukey range 
test for the F-test and the Dunn test for Kruskal-Wallis 
test). In the case of two related variables model, the 
Student’s t-test or Wilcoxon signed-rank test were 
used. The significance of differences between more 
than two variables in the related variables model was 
determined with repeated measures analysis of vari-
ance or the Friedman test.
In order to determine the interdependence, 
strength, and direction between the variables, a cor-
relation analysis was used to calculate Pearson correla-
tion coefficients. In all calculations the assumed level 
of significance was set at α = 0.05.
Results
Mean thyroid volume in US was 104.36 mL (range: 
36.23–301.09 ml, median: 92.04 mL), and in CT 
112.09 mL (range: 35.75–315.97 ml, median: 91.07 mL). 
No statistically significant difference was observed be-
tween US and CT volumetric evaluation either before 
the treatment (H = 1.74; p = 0.6291) or afterwards 
(H = 1.09; p = 0.7786). Additionally, using Bland-Atman 
plots, we assessed previously that in volumetric thyroid 
measurements US is a comparable method to CT; there-
fore, in this study US examination was established as 
a reference method [9].
The lowest total activity administered was 800 MBq 
and 4000 MBq was the highest. On average, 1806 MBq 
was administered. All patients were administered ac-
tivities higher or equal to the calculated activity. The 
mean absorbed activity calculated on the basis of goitre 
size, and iodine uptake by the thyroid was 6.16 MBq/g 
(range: 4.51–9.94 MBq/g of thyroid tissue).
Mean goitre size reduction reported in US ex-
amination was 43.18% (range: –17.23–89.66%, median: 
47.02%). In only one patient an increase in thyroid 
volume was observed after the treatment. In absolute 
values, mean thyroid volume after the treatment was 
58.66 mL (range: 10.82–203.32 mL, median: 53.20 mL) 
and differed significantly from the pre-treatment value 
(t = 7.50; p = 0.0001). 
The evaluation of total goitre reduction with time 
proved to be the best treatment results achieved a year 
after the treatment. The volume reduction changed 
significantly with time (Friedman ANOVA: 30.40; 
p = 0.0001). The greatest decrease in goitre size (relative 
reduction) was observed during the first three months 
Figure 1. Correlation between reduction level 3 months after the 
treatment and total reduction level
Rycina 1. Korelacja stopnia redukcji objętości tarczycy po 
3 miesiącach po leczeniu z całkowitym stopniem redukcji
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after the treatment. The reduction of goitre size between 
3 and 6 months after the treatment, similarly to the 
relative reduction between 6 and 12 months after the 
treatment, was significantly lower than the reduction 
reported during the first 3 months after the treatment 
(ANOVA F = 8.47; p = 0.0005).
The goitre reduction level obtained 3 months after 
the treatment correlates with the level obtained at 
the end of observation (correlation coefficient: 0.74; 
p = 0.0010) (Fig. 1).
Factors modifying the treatment efficacy were 
not determined. There was no correlation between 
goitre reduction and age (r = –0.28; p = 0.1049), 
L-T4 dosage (r = 0.19; p = 0.2859), pretreatment TSH 
level (r = 0.09; p = 0.6030), Iodine uptake (r = –0.13 
p = 0.4587), total administered 131-I activity (r = 0.14; 
p = 0.4130), absorbed 131-I activity (r = 0.14; 
p = 0.3965), goitre duration (r = –0.27 p = 0.1170), and 
goitre size before treatment (r = –0.01; p = 0.9542). No 
differences in level of thyroid reduction were observed 
between patients with positive and negative anti-
TPO and anti-TG antibodies (t = 0.44; p = 0.6625 and 
t = 0.07; p = 0.9423, respectively).
Prior to treatment 25 patients (71.4%) were euthy-
roid and the remaining 10 (28.6%) were diagnosed 
with subclinical hyperthyroidism. After the treatment 
20 patients (57.1%) remained euthyroid and 15 (42.9%) 
required L-T4 substitution due to hypothyroidism. 
Symptoms of transient hyperthyroidism were observed 
in 3 patients, and in 2 patients Graves disease was in-
duced. The latter two were excluded from the study, yet 
initially they accounted for 5.4 % of the whole group. 
In 2 patients thyroid enlargement was reported 
3 months after the completed treatment, with their 
thyroids increased in volume by 18.42 % and 2.57 %, re-
spectively. In both cases final goitre reduction was even-
tually observed. US examination during the treatment 
(between consecutive 131-I administrations) revealed 
an increased thyroid volume in 7 patients. On average, 
thyroid increased by 22.3% (range 0.63–55.03%; median 
19.58%). In none of the patients increased dyspnoea, 
stridor, or pressure sensation were observed.
Post-treatment hypothyroidism was reported in 
15 patients (42.9%). Patients from this group had ini-
tially higher TSH and lower fT4 values than those who 
remained euthyroid after the treatment (U = 28.00; 
p = 0.0001 and t = –3.84; p = 0.0005). No correlation 
was observed between anti-TPO, anti-TG, and TRAb 
antibodies and the risk of post-treatment hypothyroid-
ism. The evaluation of the other evaluated parameters 
did not reveal a higher risk of hypothyroidism. There 
was no difference in goitre size (U = 93.00; p = 0.0597), 
age (U = 100.00; p = 0.0989), iodine uptake (U = 83.00; 
p = 0.1297), total administered 131-I activity (t = –0.68; 
p = 0.4982), goitre duration (U = 122.50; p = 0.3681), 
and absorbed 131-I activity (t = 1.74; p = 0.0919) be-
tween euthyroid and hypothyroid groups.
The number of anti-TPO and anti-TG positive pa-
tients significantly increased after treatment (anti-TPO 12 
[34.29%] before vs. 15 [42.86%] after treatment p=0.0001, 
anti-TG 14 [40.00%] before vs. 24 [68.57%] after treatment 
p = 0.001). Before treatment, 6 patients (17.14%) had el-
evated TRAb without clinical and laboratory features of 
hyperthyroidism. After treatment only 1 person (3.03%), 
different from those above, presented positive TRAb re-
sults. The low percentage of positive results does not allow 
us to discuss the significance of these changes.
Discussion
Surgery still remains the gold standard of nodular, 
especially nontoxic, goitre treatment. It is undoubtedly 
the method of choice for young patients without any 
concomitant diseases. In patients with a toxic goitre an-
tithyroid drug treatment resolves metabolic problems, 
but still does not influence thyroid reduction; on the 
contrary it stimulates further goitre growth [1]. Apart 
from those patients who give their consent to surgery 
and do not have any contraindications, there are also 
those who need treatment but definitely should not 
be operated on. This group consists of elderly patients 
with numerous contraindications and those unwilling 
to give their consent to surgery. Assuming low goitre 
growth ratio (on average 10–20% per year), in patients 
with small goitre and in advanced age, observation and 
monitoring or, in some cases, antithyroid drug treat-
ment may be sufficient [10]. The need for more invasive 
therapy starts when cosmetic aspects and symptoms 
including the compression of the trachea or other struc-
tures within the neck appear [11]. In this characterised 
group the method of choice, in other words the method 
when there is no alternative because surgical treatment 
is impossible, remains radioiodine treatment.
Radioiodine treatment allows a goitre reduction of 
40–60% within 1–2 years after isotope administration 
[3, 12–14]. The range of thyroid volume reduction is 
comparable regardless of whether it is diffuse toxic [15], 
autonomous solitary toxic thyroid adenoma [16], or diffuse 
nontoxic [17, 18] and nontoxic multinodular goitre [2]. In 
EU countries (the United Kingdom, France, Belgium, the 
Netherlands, and Poland) the maximum radioiodine activ-
ity allowed in outpatient treatment is 370–800 MBq [19]. 
The used 131-I activity is determined by the 131-I uptake 
and goitre volume. Our study group consisted of elderly 
patients with long-standing, usually very large goitres, 
who required the administration of high radioiodine 
activities. In order to avoid inconvenient isolation and 
hospitalisation, a high dose of 131-I was fractionated to 
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activities allowed in outpatient treatment. The adminis-
tration of lower 131-I activities enables the therapy to be 
conducted in every centre that uses isotopes. It allows 
elderly patients to avoid hospital treatment that is avail-
able only in selected centres, often located a considerable 
distance from their place of residence. It seems to be of 
great importance, especially as the patients often suffer 
from numerous concomitant diseases, which somehow 
immobilise them.
In our study, using repeated 131-I doses in outpa-
tient treatment of large nodular goitre, we reported 
a goitre reduction of approximately 43% a year after 
the treatment. The outcome did not differ from the 
results of the studies in which high, single doses were 
used [3, 14, 20–22].
The results improved with time and were highest 
a year after the treatment. Studies with a longer obser-
vation period report increased goitre reduction in time 
from 38% during the first year to 44% after 2 years of 
observation and from 34% to 55%, respectively [12, 22]. 
The authors of the studies with a longer follow-up report 
as much as a 71.9 % reduction [21]. Verelst et al. observed 
the best results after less than a year of treatment with 
a nearly maximum effect 24 to 30 months after the 
therapy [23]. Similarly to what Nygaard et al. reported in 
toxic goitre, we observed the greatest decrease in goitre 
volume within the first 3 months after the treatment, 
with a subsequent decrease in reduction degree [2]. 
An interrelationship never described before but ob-
served in our study is the correlation between the final 
treatment results and the preliminary results obtained 
3 months after the treatment. We found that the results 
obtained a short time after the treatment can provide 
a reliable bias for predicting final results. This informa-
tion may be of great clinical importance, when making 
a decision regarding the continuation of treatment and 
the administration of the next 131-I dose. 
The dependence of treatment results on the other 
parameters still remains an unresolved issue. Accord-
ing to Le Moli et al., treatment results depend on the 
administered 131-I activity [24]. In our study, however, 
we did not observe any correlation between the admin-
istered 131-I activity and the treatment results. Similarly 
to us, despite using a complicated algorithm to calculate 
131-I activity, Bonnema et al. did not show any rela-
tion between the administered 131-I activity and the 
obtained results [20]. Jarlov et al. questioned the sense 
of precise 131-I activity calculation. Comparing the 
effects of 131-I toxic goitre treatment in the administra-
tion of a fixed dose, based on gland size assessment by 
palpation only, to the precise calculation of the activity 
based on the morphology of the gland, iodine uptake, 
and US estimation of goitre size, they did not observe 
any differences [25]. Analysing the interdependence 
between the initial goitre size and treatment results, we 
did not find any correlation. Based on the publications 
by Danish researchers, we expected treatment results 
to decrease with the increase in initial goitre volume 
[22, 24]. Le Moli et al. showed a correlation of treatment 
results with goitre duration and patient’s age as indirect 
factors determining the goitre size [24]. In our study, 
we neither observed a correlation between thyroid 
volume and treatment results nor a correlation between 
the treatment results and duration of the disease or the 
age of the patients. Moreover, we did not find a cor-
relation between the L-T4 dosage administered before 
the treatment, the hormonal function before surgery, 
iodine uptake, smoking, positive anti-TG, and anti-TPO 
antibodies and thyroid volume reduction. Given the 
obtained results, based on our work, the reason for the 
observed discrepancies in thyroid volume reduction, 
ranging from a 17.23% goitre growth to an 89.66% goitre 
reduction, remains unexplained. 
Similarly to Le Moli et al., we did not observe any 
longer the cases of subclinical hyperthyroidism after the 
treatment [24]. In the study, after 131-I treatment 42.9% 
of the patients required L-T4 substitution, including 
those with initial post-strumectomy hypothyroidism. 
Considering TSH as a goitre growth factor, we initiated 
L-T4 treatment in all patients whose TSH level exceeded 
4 μIU/mL, as did Wesche et al. [22]. All patients submit-
ted to L-T4 therapy were classified as hypothyroid, 
with a possibly overestimated percentage of hypothy-
roidism cases reported in the study. Post-treatment 
hypothyroidism risk factors were not determined. We 
established that the administered 131-I activity did not 
affect the risk of hypothyroidism, and neither did the 
thyroid volume, patient’s age, iodine uptake, goitre du-
ration, or anti-TPO and anti-TG antibodies. We observed 
that patients with hypothyroidism after the treatment 
initially had higher TSH and lower fT4 levels. These 
results confirm the conclusions drawn by Wesche et al. 
that subclinical hyperthyroidism is a protective factor 
against hypothyroidism after 131-I treatment [26].
An early complication following 131-I treatment 
is transient thyrotoxicosis resulting from thyroid cell 
damage. In the available literature, the incidence of 
this complication is estimated at between 0% and 28% 
[13, 17, 22, 24]. In our study, 8.57% of the patients were 
diagnosed with hyperthyroidism caused by transient, 
self-limiting form of thyroiditis. This complication had 
no clinical implications. However, such risk cannot be 
excluded, especially in patients with heart rhythm dis-
turbances and heart failure, in whom even transient 
thyrotoxicosis may significantly deteriorate their condi-
tion. In 2 patients the treatment induced autoimmune 
thyroiditis. In the whole group, the risk of this complica-
tion was estimated to be 5.41%. Nygaard et al. presented 
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similar results (5%) of Graves-like hyperthyroidism 
incidence after the 131-I treatment in a retrospective 
study of 191 patients with a nontoxic goitre [27]. Apart 
from ours, to the authors’ best knowledge, there is 
only one case study that describes GO induction after 
131-I treatment of nontoxic goitre [28]. Clinically, at the 
time of 131-I administration the patient did not show 
any symptoms of Graves hyperthyroidism or GO. She 
was a smoker, which theoretically increased the risk of 
GO [29]. However, even in 131-I treatment of Graves' 
disease severe GO progression, especially in patients 
without initial GO symptoms, is rare [30]. In one patient 
after treatment we observed an increase of TRAb, while 
a reduction of these antibodies in 6 other patients was 
noticed. Despite the described TRAb increase following 
radioiodine therapy for Graves disease [31, 32] and in 
thyroid cancers [33, 34], autonomous thyroid disease 
[35], as well as nontoxic goitre [36], we did not obtain 
such results. Long observation time, assessment at only 
two time points, or advanced patient’s age may be of 
importance for these results.
It should be taken into consideration that 131-I 
administration, especially in case of very large or sub-
sternal goitres, entails a risk of thyroid enlargement. 
Numerous authors encourage the use of this method, 
but tend to undermine the significance of the prob-
lem. A week after 131-I administration, Bonnema et al. 
observed thyroid enlargement in 9 out of 23 patients, 
with increased thyroid volume of more than 5% of the 
initial value in 4 cases [20]. Following the nontoxic goitre 
131-I treatment, thyroid enlargement of more than 5% 
was described by Nygaard et al. in 9 out of 130 patients, 
with the median enlargement being 23% (11–60%) [2]. 
In our work, thyroid enlargement was observed in 
2 patients (5.71%) 3 months after the treatment, but it 
did not exceed 20% of the initial volume. During the 
treatment, thyroid enlargement by a maximum of 55% 
was reported in 7 patients (20%). In none of the patients 
increased dyspnoea, stridor, or pressure sensation in 
the neck were observed. Eventually, all patients were 
reported to have their goitres decreased in size. The 
above results should not discourage 131-I administra-
tion, but rather encourage monitoring patients more 
frequently during and after the treatment. 
A complication after low 131-I activity administra-
tion, to the best of our knowledge previously never 
reported, is radiation parotid gland damage. In our 
work this complication was observed in one case after 
the third 131-I administration. This patient had previ-
ously been suspected of Sjögren’s syndrome but had 
never been fully diagnosed. In our opinion, previous 
salivary gland damage may increase the risk of radia-
tion damage of the salivary gland even if the patient is 
administered low 131-I activities. 
Conclusions
Fractionated 131-I treatment of large nodular goitres 
is safe, effective, and, what needs to be emphasised, 
convenient method of treatment for the patient. The 
efficacy of the therapy with a reduction of 43% will not 
differ from high, single-dose treatment. The therapy is 
a good alternative to surgery and may be successfully 
conducted by dose fractionation in every outpatient 
centre that uses radioisotopes for therapy.
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